These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 19065621

  • 21. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J.
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
    Song IH, Maksymowych WP.
    Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
    [Abstract] [Full Text] [Related]

  • 23. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J.
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [Abstract] [Full Text] [Related]

  • 24. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis.
    Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J.
    Ann Rheum Dis; 2004 Dec; 63(12):1670-2. PubMed ID: 15547093
    [Abstract] [Full Text] [Related]

  • 25. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 26. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 27. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Reddig J, Sieper J, Braun J.
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [Abstract] [Full Text] [Related]

  • 28. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [Abstract] [Full Text] [Related]

  • 29. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [Abstract] [Full Text] [Related]

  • 30. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

  • 31. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J, Rudwaleit M.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [Abstract] [Full Text] [Related]

  • 32. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.
    Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A.
    Curr Opin Rheumatol; 2012 May; 24(3):290-8. PubMed ID: 22418743
    [Abstract] [Full Text] [Related]

  • 33. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J.
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [Abstract] [Full Text] [Related]

  • 34. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB.
    Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
    [Abstract] [Full Text] [Related]

  • 35. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 36. Smoking did not modify the effects of anti-TNF treatment on health-related quality of life among Australian ankylosing spondylitis patients.
    Kydd AS, Chen JS, Makovey J, Chand V, Henderson L, Buchbinder R, Lassere M, March LM.
    Rheumatology (Oxford); 2015 Feb; 54(2):310-7. PubMed ID: 25173348
    [Abstract] [Full Text] [Related]

  • 37. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 38. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 39. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.
    Ann Rheum Dis; 2013 Jul 15; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract] [Full Text] [Related]

  • 40. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM, Bell AL, Cairns AP.
    Rheumatol Int; 2007 Dec 15; 28(2):199-200. PubMed ID: 17602229
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.